Publications by authors named "Kenzo Muramoto"

Study Objectives: Patients with chronic insomnia may respond differently to therapeutic modalities. This study examined differences in response of individuals with 2 insomnia phenotypes-short sleep duration (I-SSD; < 6 hours) and normal sleep duration (I-NSD; ≥ 6 hours) determined by polysomnography-to treatment with lemborexant and zolpidem tartrate extended-release 6.25 mg (zolpidem ER), compared with placebo.

View Article and Find Full Text PDF

Purpose: Medication discontinuation for patients with Alzheimer's dementia (AD) influences treatment efficacy. This study aimed to evaluate the effect of psychoeducational intervention (PI) on donepezil retention rates and identify the factors associated with donepezil continuation in patients with AD.

Patients And Methods: One hundred and seventeen patients with AD were randomly allocated to the PI (n = 58) or standard care (SC; n = 59) groups.

View Article and Find Full Text PDF

Most conventional insomnia medications are gamma-aminobutylic acid receptor agonists. However, physical dependence is a concern and one of the major limiting factors for long-term treatment. The dual orexin receptor antagonists, suvorexant and lemborexant, were recently approved for treating chronic insomnia, giving a novel pharmacotherapeutic option.

View Article and Find Full Text PDF

Clinical trial data of Carmustine implant (Gliadel Wafer) in Japanese patients with malignant glioma are limited; thus, we conducted a postmarketing surveillance study to evaluate the safety of Gliadel in real-world clinical practice in Japan. In this postmarketing surveillance study, all patients who received Gliadel placement for malignant glioma surgeries from its market launch (January 9, 2013) to July 10, 2013 were enrolled from 229 institutions using a central registration system. Up to eight wafers of Gliadel (containing 61.

View Article and Find Full Text PDF

Background: It was reported that eribulin regulates the tumor microenvironment, including the immune system, by inducing vascular remodeling. Lymphocyte counts are a critical index of immune response in patients. The non-Asian, global EMBRACE study has suggested that baseline absolute lymphocyte count (ALC) may be a predictor of the survival benefit of eribulin in breast cancer patients.

View Article and Find Full Text PDF

Orexin receptor antagonists have been approved for insomnia, and the insomnia pharmacotherapy is being greatly progressed. Orexin is a neuropeptide produced in the lateral hypothalamic area, and its physiological role has been suggested to be a key mediator controlling the sleep-wake state. Orexin receptor antagonists are thought to induce physiological sleep by acting specifically on the sleep-wake cycle.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on patients with psoriatic arthritis (PsA) to assess axial joint involvement using MRI and the impact of 24-week adalimumab treatment.
  • It involved 37 PsA patients, revealing high rates of spondylitis (91%) and varying degrees of sacroiliitis, with the thoracic spine being the most affected area.
  • The treatment with adalimumab significantly improved both the number of spondylitis sites and the severity of sacroiliitis after 24 weeks.
View Article and Find Full Text PDF
Article Synopsis
  • Eribulin is a synthetic drug used to treat locally advanced or metastatic breast cancer, showing potential effects on the tumor's immune environment and possibly indicating better survival predictions based on lymphocyte counts.
  • In a study involving 751 patients, those with higher absolute lymphocyte counts (≥1500/µl) experienced significantly prolonged overall survival when treated with eribulin, while those with counts below this threshold did not show a notable difference in survival outcomes compared to other treatments.
  • The analysis suggests baseline absolute lymphocyte count could serve as an independent predictor of overall survival in eribulin-treated patients, highlighting its clinical significance since it's non-invasive to assess.
View Article and Find Full Text PDF

To evaluate the efficacy and safety of adalimumab in psoriatic arthritis (PsA) patients in Japan. In this open-label, single-arm study conducted at six sites from October 2014 to June 2016 (UMIN000016543), PsA patients (≥20 years old) with inadequate response to nonsteroidal anti-inflammatory drugs received adalimumab subcutaneously (80 mg initially, then 40 mg every other week; 24 weeks total). Primary endpoint was American College of Rheumatology 20% improvement (ACR20) response rate at week 12.

View Article and Find Full Text PDF

Chemokine systems modulate inflammatory and immune responses in inflammatory bowel disease (IBD). The colons of IBD patients show increased levels of fractalkine (FKN) and high numbers of FKN receptor-positive (CX3CR1+) cells; however, the FKN-CX3CR1 axis's role in intestinal inflammation, especially in intravascular leukocyte behaviors, still remains unclear. Here, we show that interruption of the FKN-CX3CR1 axis by anti-FKN monoclonal antibody (mAb) ameliorates murine colitis through regulation of intravascular monocyte behaviors in murine colitis models.

View Article and Find Full Text PDF
Article Synopsis
  • Inflammatory bowel disease (IBD) includes conditions like ulcerative colitis and Crohn's disease, which are marked by chronic inflammation in the intestines due to leukocyte adhesion facilitated by integrins.
  • Calreticulin (CRT) plays a role in this process by activating integrin α subunits, but its exact relationship with IBD is not well understood.
  • A new small molecule, ER-464195-01, has been found to inhibit CRT's interaction with integrins, reducing inflammation and leukocyte infiltration in IBD mouse models, suggesting a potential new treatment approach.
View Article and Find Full Text PDF

Recent decades have witnessed a rapid worldwide increase in chronic inflammatory disorders such as asthma. CD4 T helper 2 cells play critical roles in the pathogenesis of allergic airway inflammation, and CD69 expression on activated CD4 T cells is required to induce allergic inflammation in tissues. However, how CD69 mechanistically controls allergic inflammation remains poorly defined.

View Article and Find Full Text PDF

Adult T cell leukemia/lymphoma (ATL) is a peripheral T cell neoplasm of largely unknown genetic basis, associated with human T cell leukemia virus type-1 (HTLV-1) infection. Here we describe an integrated molecular study in which we performed whole-genome, exome, transcriptome and targeted resequencing, as well as array-based copy number and methylation analyses, in a total of 426 ATL cases. The identified alterations overlap significantly with the HTLV-1 Tax interactome and are highly enriched for T cell receptor-NF-κB signaling, T cell trafficking and other T cell-related pathways as well as immunosurveillance.

View Article and Find Full Text PDF

Introduction: Chemerin is a chemotactic agonist identified as a ligand for ChemR23 that is expressed on macrophages and dendritic cells (DCs). In this study, we analyzed the expression of chemerin and ChemR23 in the synovium of rheumatoid arthritis (RA) patients and the stimulatory effects of chemerin on fibroblast-like synoviocytes (FLSs) from RA patients.

Methods: Chemerin and ChemR23 expression in the RA synovium was ascertained by immunohistochemistry and Western blot analysis.

View Article and Find Full Text PDF

E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,10-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione)] is a novel anti-inflammatory agent that has potent inhibitory effects on the production of proinflammatory cytokines from leukocytes and antiproliferative activity on keratinocytes. To characterize the in vivo pharmacological activity of E6201, topically administered E6201 was evaluated in several different animal models of dermatitis. E6201 formulated as an ointment or cream showed dose-dependent inhibition of croton oil-induced acute edema formation and neutrophil infiltration into mouse skin.

View Article and Find Full Text PDF
Article Synopsis
  • Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, involve chronic inflammation of the gastrointestinal tract, marked by cycles of flare-ups and remission.
  • A key factor in the development of IBD is the infiltration of leukocytes (white blood cells) into the intestine, which is regulated by specific chemokines and their receptors.
  • The review highlights potential therapeutic targets, particularly focusing on the CX3CL1-CX3CR1 axis and other chemokine pathways (CCL20-CCR6, CCL25-CCR9, CXCL10-CXCR3) for treating IBD.
View Article and Find Full Text PDF

The goal of this study is to identify a novel inhibitor with anti-inflammatory and antiproliferative properties for the treatment of psoriasis. Compound f152A1 [(3S,5Z,8S,11E)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-tetrahydro-1H-benzo[c][1]oxacyclotetradecine1,7(8H)-dione] was identified as the main active metabolite with strong inhibitory activity against tumor necrosis factor-alpha (TNFalpha) transcription in a fraction originated from the fermentation broth of the fungus Curvularia verruculosa. Although active in cell-based assays, f152A1 was unstable in plasma and liver microsome preparations, thus limiting its pharmaceutical utilization.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with massive infiltration of inflammatory cells in the synovium of multiple joints. We and others have shown that fractalkine (FKN/CX3CL1), a chemokine expressed on fibroblast-like synoviocytes and endothelial cells in RA synovium, may contribute to the accumulation of T cells, macrophages, and dendritic cells, which express CX3CR1, the receptor for FKN. This interaction might be involved in adhesion of the inflammatory cells to endothelial cells, migration into the synovium, and cytokine production.

View Article and Find Full Text PDF

Novel piperidine carboxylic acid derivatives of 10H-pyrazino[2,3-b][1,4]benzothiazine were prepared and evaluated for their inhibitory activity on the upregulation of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1). Replacement of the methanesulfonyl group on the piperidine ring of previously prepared derivatives with a carboxylic acid-containing moiety resulted in a number of potent adhesion molecule inhibitors. Of these, (anti) [3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methyl-3-azabicyclo[3.

View Article and Find Full Text PDF

During a search for novel, orally-active inhibitors of upregulation of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), we found a new series of 10H-pyrazino[2,3-b][1,4]benzothiazine derivatives to be potent ICAM-1 inhibitors. Of these compounds, N-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]-N',N'-dimethylsulfamide 7p showed the potent oral inhibitory activities against neutrophil migration in a murine interleukin-1 (IL-1) induced paw inflammation model. The synthesis and structure-activity relationships of these amide derivatives are described.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Kenzo Muramoto"

  • - Kenzo Muramoto's recent research focuses on the efficacy and safety of novel pharmacological treatments for sleep disorders, dementia, and inflammatory diseases, with a particular emphasis on orexin receptor antagonists and their application in chronic insomnia and Alzheimer's disease treatment.
  • - His studies reveal that treatment responses in insomnia differ based on sleep duration phenotypes, highlighting diverse efficacy of lemborexant compared to traditional medications like zolpidem, while psychoeducational interventions improve donepezil retention rates in Alzheimer's patients.
  • - Additionally, Muramoto investigates the role of immune metrics, such as lymphocyte counts, in predicting survival outcomes in cancer patients, contributing to the understanding of immune responses in cancer treatment efficacy.